PRTA Prothena Corporation plc

36.64
+0.05  (0%)
Previous Close 36.59
Open 37.19
Price To book 3.16
Market Cap 1408689323
Shares 38,446,761
Volume 99,549
Short Ratio 11.10
Av. Daily Volume 349,178

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171183650
  2. 8-K - Current report 171183526
  3. 8-K - Current report 171107619
  4. CT ORDER - Confidential treatment order 171073829
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171015832

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 planned for 2Q 2017.
PRX002 (PASADENA)
Parkinson's disease
Phase 1b data released September 28, 2017 - insufficient meaningful clinical effect for further development.
PRX003
Psoriatic Arthritis
Phase 3 trial fully enrolled - noted August 8, 2017. Data likely due 2020.
NEOD001 VITAL
AL Amyloidosis
Phase 2b data due 2Q 2018.
NEOD001 PRONTO
Previously-treated patients with AL amyloidosis and persistent cardiac dysfunction

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171183650
  2. 8-K - Current report 171183526
  3. 8-K - Current report 171107619
  4. CT ORDER - Confidential treatment order 171073829
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171015832
  6. 8-K - Current report 171015103
  7. S-8 - Securities to be offered to employees in employee benefit plans 17863883
  8. 8-K - Current report 17863838
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 17826621
  10. 8-K - Current report 17826413